title: New-onset type 1 diabetes mellitus and anti-aquaporin-4 antibody positive optic neuritis associated with type 1 interferon therapy for chronic hepatitis C.
abstract: A 60-year-old woman developed type 1 diabetes mellitus and anti-aquaporin-4 antibody positive optic neuritis during type 1 interferon therapies for chronic hepatitis C. The diabetes mellitus was elicited by interferon-α plus ribavirin therapy, while the optic neuritis was induced after interferon-β treatment, followed by interferon-α and ribavirin therapy. It is possible that type 1 interferons lead to the onset of the two autoimmune diseases by inducing disease-specific autoantibodies. Autoimmune disease is an infrequent complication of type 1 interferon treatment; however, once it has occurred, it may result in severe impairments. Patients undergoing type 1 interferon therapy should therefore be carefully monitored for any manifestations of autoimmune diseases.
authors.affiliation: Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Japan.
authors.forename: Tomoya
authors.initials: T
authors.lastname: Kawazoe
authors.forename: Manabu
authors.initials: M
authors.lastname: Araki
authors.forename: Youwei
authors.initials: Y
authors.lastname: Lin
authors.forename: Masafumi
authors.initials: M
authors.lastname: Ogawa
authors.forename: Tomoko
authors.initials: T
authors.lastname: Okamoto
authors.forename: Takashi
authors.initials: T
authors.lastname: Yamamura
authors.forename: Masato
authors.initials: M
authors.lastname: Wakakura
authors.forename: Miho
authors.initials: M
authors.lastname: Murata
mesh_terms: D000888:Antibodies, Anti-Idiotypic / Q000097:blood*; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use; D051401:Aquaporin 4 / Q000276:immunology*; D003922:Diabetes Mellitus, Type 1 / Q000139:chemically induced* / Q000175:diagnosis; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects* / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use; D016899:Interferon-beta / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D009902:Optic Neuritis / Q000139:chemically induced* / Q000175:diagnosis / Q000276:immunology*; D012254:Ribavirin / Q000627:therapeutic use
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000998:Antiviral Agents; D051401:Aquaporin 4; D007370:Interferon Type I; D016898:Interferon-alpha; D012254:Ribavirin; D016899:Interferon-beta